Evaluating the impact of PSA as a selection criteria for nerve sparing radical prostatectomy in a screened cohort - Abstract

Purpose: We investigated whether NS-RP increased risk of PSA failure and whether PSA should be included as a selection criterion for NS.

Methods: We evaluated 357 consecutive men with screen-detected PC who underwent open RP without adjuvant radiotherapy between 9/11/2001 and 12/30/2008. Criteria for NS included Gleason score ≤ 3 + 4, percentage of positive biopsies (PPB) ≤ 50%, percentage of core involvement ≤ 50%, nonapical location, no perineural invasion, and no palpable disease on pre- or intraoperative exam but did not include a PSA threshold. Cox multivariable regression assessed whether increasing PSA or unilateral- or bilateral-NS versus non-NS-RP was associated with PSA failure adjusting for prognostic factors.

Results: After a median follow-up of 3.96 years, 34 men sustained PSA failure (9.5%). Increasing PSA was significantly associated with increased risk of PSA failure in the interaction model (adjusted hazard ratio (AHR): 1.09 [95% CI: 1.03-1.16]; P = 0.005), whereas unilateral (AHR: 1.24 [95% CI: 0.36-4.34]; P = 0.73) or bilateral NS (AHR: 0.41 [95% CI: 0.06-2.59]; P = 0.34) versus non-NS RP was not.

Conclusion: NS-RP in a screened cohort did not increase risk of PSA failure using NS criteria not including PSA.

Written by:
Tanguturi SK, Chen MH, Loffredo M, Richie JP, D'Amico AV.   Are you the author?
Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA 02115, USA; Brigham and Women's Hospital, 75 Francis Street, ASB1 L2, Boston, MA 02115, USA; Department of Statistics, University of Connecticut, Storrs, CT 06269, USA; Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA; Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA 02115, USA.

Reference: Prostate Cancer. 2014;2014:395078.
doi: 10.1155/2014/395078


PubMed Abstract
PMID: 24829803

UroToday.com Prostate Cancer Section